31.7 C
New York
Sunday, June 14, 2026

Tag: laws

newssourceFORcompanyinformationcontent1marketreleases

Firm Capital Property Trust Files (Final) Base Shelf Prospectus

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Power Metallic Mines Announces Closing of Brokered LIFE Offering for Gross Proceeds of C$28.2 Million and Welcomes Eric Sprott as a New Shareholder

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, June 10, 2026 /CNW/ - Power...

Kimco Realty OP, LLC Announces Proposed Exchangeable Senior Notes Offering

JERICHO, N.Y., June 10, 2026 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM) today announced that its operating subsidiary, Kimco Realty OP, LLC (“Kimco OP”), intends to offer, subject to market and other conditions, $500,000,000 aggregate principal amount of exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Kimco Realty Corporation (“Kimco”) will fully and unconditionally guarantee the notes on a senior, unsecured basis. Kimco OP also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $75,000,000 aggregate principal amount of notes.

Vivakor Announces Flagship Remediation Processing Center in Houston, Texas to be Commercially Operational in the Third Quarter of 2026

New Joint Venture Partnership Agreement Seeks Further Expansion

North American Construction Group Ltd. Announces Pricing of Private Placement Offering of $200 Million Senior Unsecured Notes

ACHESON, Alberta, June 10, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG”) (TSX: NOA / NYSE: NOA) announced today that it has entered into an underwriting agreement to sell, pursuant to a private placement offering (the “Offering”), $200 million aggregate principal amount of 7.00% Senior Unsecured Notes due June 16, 2031 (the “Notes”). The Notes will be issued at a price of $1,000 per $1,000 of Notes. The Notes will accrue interest at the rate of 7.00% per annum, payable in cash in equal payments semi-annually in arrears each June 16 and December 16, commencing on December 16, 2026. The Notes will be issued pursuant to an indenture to be entered into between NACG and Computershare Trust Company of Canada, as trustee.

Hemlo Mining Corp. Announces Graduation to the Toronto Stock Exchange

Trading to begin at market open on Monday, June 15, 2026TORONTO, June 10, 2026 /CNW/ - Hemlo Mining Corp. (TSXV: HMMC) (OTCQX: HMMCF) (the...

Vision Marine Technologies Extends Nextfour Agreement Through 2029 to Strengthen E-Motion™ Connected Platform Capabilities

Technology / E-Motion™ Platform IntelligenceVision Marine is extending a key display supply and integration relationship through 2029, supporting the connected digital interface of its...

Tilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in Germany

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany 
New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.

ING rolls out global subscription banking model

ING rolls out global subscription banking model

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn...

GeneDx (WGS) Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLaws

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers